RECURRENT RESPIRATORY PAPILLOMATOSIS
Clinical trials for RECURRENT RESPIRATORY PAPILLOMATOSIS explained in plain language.
Never miss a new study
Get alerted when new RECURRENT RESPIRATORY PAPILLOMATOSIS trials appear
Sign up with your email to follow new studies for RECURRENT RESPIRATORY PAPILLOMATOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene therapy retreatment shows promise for rare throat tumor condition
Disease control Recruiting nowThis study tests a gene therapy called Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP), a rare condition causing non-cancerous throat tumors that often come back after surgery. The study has two groups: one checks how the virus used in the t…
Matched conditions: RECURRENT RESPIRATORY PAPILLOMATOSIS
Phase: PHASE4 • Sponsor: Precigen, Inc • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New drug combo aims to shrink HPV-Caused throat tumors
Disease control Recruiting nowThis early-phase study tests two drugs, lenvatinib and pembrolizumab, in 20 people with HPV-related recurrent respiratory papillomatosis (RRP) that has spread to the lungs. The goal is to see if the combination can shrink growths and reduce the need for repeated surgeries. The st…
Matched conditions: RECURRENT RESPIRATORY PAPILLOMATOSIS
Phase: EARLY_PHASE1 • Sponsor: Yale University • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
First-in-Human trial tests custom vaccine for debilitating throat condition
Disease control Recruiting nowThis early-stage study is testing a new, personalized vaccine made from a patient's own immune cells. It aims to see if the vaccine is safe and can trigger an immune response against the virus that causes recurrent, non-cancerous growths in the throat. The study will enroll 9 adu…
Matched conditions: RECURRENT RESPIRATORY PAPILLOMATOSIS
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC